Neurotech Insights
Covering Drugs, Devices, and Diagnostics for the Brain and Nervous System
|
| Subscriber Login
|
Inside This Issue: Attention Deficit Disorder
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: Neurotech Industry Organization Post-Election Policy Update
Featured Company: PsychoGenics, Inc.
Subscribe now to access over 30 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Awaits New Nonstimulant Options for Attention Deficit Disorder
ADHD or Attention Deficit Hyperactivity Disorder remains a controversial diagnosis. Despite many guidelines and attempts at objectivity, an international consensus has not been reached on the nature of this affliction. Even if we exclude the minority view that ADHD is not a real medical condition, large discrepancies remain between various constituencies. Many believe the condition is real but over-diagnosed or vastly over-medicated; while others seem to think it is widely ignored and under-diagnosed. Yet others are concerned at the rapid growth in a diagnosis that has few objective benchmarks and is treated with a class of addictive drugs that are favorites for recreational use and abuse. This article outlines promising treatments in development for ADHD...
PsychoGenics: Leveraging Animal Behavior Expertise to Identify New Treatments
PsychoGenics, Inc. was founded 10 years ago by the well respected addiction researcher Eric Nestler, MD, PhD, and Henry Jarecki, MD. Dr. Nestler, Professor of Neuroscience and Director of the Mount Sinai Brain Institute, recognized the need for a company that would provide CNS behavioral testing services in rodents. PsychoGenics, which was primarily supported with funding from a few individuals, set out to provide such services to biotechnology companies and Big Pharma. They now have over 100 clients. Over the past ten years, the company has developed more than 50 validated in vivo tests. It has also realized it could leverage its expertise in behavior to build a sustainable competitive advantage in drug discovery...
Market Highlights: Holiday Buying Begins
People may not be buying presents this year, but with mountains of money, Big Pharma is ready to make some purchases this holiday season. A number of deals, anticipated for some time, finally got done this month including Roche’s acquisition of Memory and King’s purchase of Alpharma (see stories, page 10). A snowballing effect can be expected as companies move to buy at the bottom before their competitors. Many companies with partnering agreements will see that they can save money in milestone payments and ensure continuation of product development by simply buying the company. Anticipation of buyouts is likely to provide a rebound in some stock prices. We are publishing the full “Neurotech Universe” of public companies on the three major exchanges this month (see page 15) to highlight opportunities across the sector...
Companies Covered In This Issue Include: Accera, Intelect Medical, NeuroNexus, Philips, Intellect Neurosciences, Elan, Wyeth, Roche, Abbott, Orexigen, UCB , Knopp, Zacharon, Enteromedics, Resolvyx, TorreyPines, King, Alpharma, Eli Lilly, Shire, Addrenex, NeuroSearch, GlaxoSmithKline, Cortex Pharmaceuticals, PsychoGenics, Psylin, Amylin, Sosei, Johnson & Johnson, Cephalon, Ortho-McNeil, Novartis, Alseres, Anesiva, Ceregene, Merck, Avigen, Jazz, Alexza, Targacept, Evotec, XTL, Vanda, Neuromed, Somaxon, Xenoport, Pain Therapeutics, Sangamo, Pfizer Solvay, Sygnis, Second Sight, Theraquest, Eisai, RhinoCyte, Psyadon and more.
Holiday Promotion - New subscribers in December recieve a free iPod Nano!
Subscribe Now:
|
|
